IMARC Group, a leading market research company, has recently releases report titled “Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global viral vector manufacturing market growth, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How Big is the Viral Vector Manufacturing Market?
| Report Attributes | Details |
| Market Size in 2022 | US$ 961 Million |
| Market Forecast in 2028 | US$ 3,975 Million |
| Growth rate (2023 to 2028) | CAGR of 24.9% |
| Base Year of the Analysis | 2022 |
| Forecast Period | 2023-2028 |
What is Viral Vector Manufacturing?
A viral vector is a tool deployed by molecular biologists to deliver genetic materials into cells. It is widely employed in cell and gene therapy to substitute defective genes for curing genetic disorders. It also expresses and presents pathogenic antigens by mimicking a natural infection for developing an immune response. In addition, it is used in treating various diseases, such as metabolic diseases, heart defects, neurodegenerative disorders, and oncolytic therapies to target and **** tumor cells. At present, viral vector manufacturing finds applications in gene therapy, life science research, and vaccinology across the globe.
Request Free Sample Copy of This Report: https://www.imarcgroup.com/viral-vector-manufacturing-market/requestsample
What are the growth prospects and trends in the viral vector manufacturing industry?
The market is primarily driven by the growing prevalence of chronic diseases such as genetic disorders, cancer, and infectious diseases. In addition, the increasing consumption of alcohol due to the sedentary lifestyles of individuals is contributing to the market growth. Moreover, as viral vectors are efficient carriers of virus-disabling sequences, they are widely used to provide ***-inhibiting transgenes to human hematopoietic stem cells (HSCs), which represents another major growth-inducing factor.
Besides this, the increasing inclination toward clinical studies undertaken on viral vectors and the growing use of viral vectors in novel drug delivery is propelling the market growth. Along with this, governments are launching campaigns to create awareness regarding viral vector vaccines among individuals and improving the regulatory environment through changes that are accelerating the product adoption rate.
Furthermore, extensive research and development (R&D) activities and mergers and acquisitions (M&A) among key players to increase their overall sales and profitability are influencing the global market outlook.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Type:
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Others
Breakup by Disease:
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Application:
- Gene Therapy
- Vaccinology
Breakup by End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: [email protected]
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/